Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Effects of interesterified lipid design on the short/medium chain fatty acid hydrolysis rate and extent (in vitro).

Acquistapace S, Patel L, Patin A, Forbes-Blom E, Cuenoud B, Wooster TJ.

Food Funct. 2019 Jul 17;10(7):4166-4176. doi: 10.1039/c9fo00671k.

PMID:
31241123
2.

Discovery and validation of temporal patterns involved in human brain ketometabolism in cerebral microdialysis fluids of traumatic brain injury patients.

Eiden M, Christinat N, Chakrabarti A, Sonnay S, Miroz JP, Cuenoud B, Oddo M, Masoodi M.

EBioMedicine. 2019 Jun;44:607-617. doi: 10.1016/j.ebiom.2019.05.054. Epub 2019 Jun 13.

3.

Nutrient pattern analysis in critically ill patients using Omics technology (NAChO) - Study protocol for a prospective observational study.

Schefold JC, Messmer AS, Wenger S, Müller L, von Haehling S, Doehner W, McPhee JS, Fux M, Rösler KM, Scheidegger O, Olariu R, Z'Graggen W, Rezzi S, Grathwohl D, Konz T, Takala J, Cuenoud B, Jakob SM.

Medicine (Baltimore). 2019 Jan;98(1):e13937. doi: 10.1097/MD.0000000000013937.

4.

Modulation of cerebral ketone metabolism following traumatic brain injury in humans.

Bernini A, Masoodi M, Solari D, Miroz JP, Carteron L, Christinat N, Morelli P, Beaumont M, Abed-Maillard S, Hartweg M, Foltzer F, Eckert P, Cuenoud B, Oddo M.

J Cereb Blood Flow Metab. 2018 Oct 24:271678X18808947. doi: 10.1177/0271678X18808947. [Epub ahead of print]

PMID:
30353770
5.

Nutritional Ketosis Increases NAD+/NADH Ratio in Healthy Human Brain: An in Vivo Study by 31P-MRS.

Xin L, Ipek Ö, Beaumont M, Shevlyakova M, Christinat N, Masoodi M, Greenberg N, Gruetter R, Cuenoud B.

Front Nutr. 2018 Jul 12;5:62. doi: 10.3389/fnut.2018.00062. eCollection 2018.

6.

An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.

Beattie D, Beer D, Bradley ME, Bruce I, Charlton SJ, Cuenoud BM, Fairhurst RA, Farr D, Fozard JR, Janus D, Rosethorne EM, Sandham DA, Sykes DA, Trifilieff A, Turner KL, Wissler E.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6280-5. doi: 10.1016/j.bmcl.2012.07.096. Epub 2012 Aug 4.

PMID:
22932315
7.

Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.

Bruce I, Akhlaq M, Bloomfield GC, Budd E, Cox B, Cuenoud B, Finan P, Gedeck P, Hatto J, Hayler JF, Head D, Keller T, Kirman L, Leblanc C, Le Grand D, McCarthy C, O'Connor D, Owen C, Oza MS, Pilgrim G, Press NE, Sviridenko L, Whitehead L.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5445-50. doi: 10.1016/j.bmcl.2012.07.042. Epub 2012 Jul 17.

PMID:
22863202
8.

Targeting of an interrupted polypurine:polypyrimidine sequence in mammalian cells by a triplex-forming oligonucleotide containing a novel base analogue.

Semenyuk A, Darian E, Liu J, Majumdar A, Cuenoud B, Miller PS, Mackerell AD Jr, Seidman MM.

Biochemistry. 2010 Sep 14;49(36):7867-78. doi: 10.1021/bi100797z.

9.

A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.

Beattie D, Bradley M, Brearley A, Charlton SJ, Cuenoud BM, Fairhurst RA, Gedeck P, Gosling M, Janus D, Jones D, Lewis C, McCarthy C, Oakman H, Stringer R, Taylor RJ, Tuffnell A.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5302-7. doi: 10.1016/j.bmcl.2010.06.136. Epub 2010 Jul 1.

PMID:
20655218
10.

The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.

Baur F, Beattie D, Beer D, Bentley D, Bradley M, Bruce I, Charlton SJ, Cuenoud B, Ernst R, Fairhurst RA, Faller B, Farr D, Keller T, Fozard JR, Fullerton J, Garman S, Hatto J, Hayden C, He H, Howes C, Janus D, Jiang Z, Lewis C, Loeuillet-Ritzler F, Moser H, Reilly J, Steward A, Sykes D, Tedaldi L, Trifilieff A, Tweed M, Watson S, Wissler E, Wyss D.

J Med Chem. 2010 May 13;53(9):3675-84. doi: 10.1021/jm100068m.

PMID:
20402514
11.

Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?

Lombardi D, Cuenoud B, Krämer SD.

Eur J Pharm Sci. 2009 Dec 8;38(5):533-47. doi: 10.1016/j.ejps.2009.10.001. Epub 2009 Oct 9.

PMID:
19819331
12.

Interaction kinetics of salmeterol with egg phosphatidylcholine liposomes by surface plasmon resonance.

Lombardi D, Cuenoud B, Wunderli-Allenspach H, Krämer SD.

Anal Biochem. 2009 Feb 15;385(2):215-23. doi: 10.1016/j.ab.2008.11.011. Epub 2008 Nov 19.

PMID:
19084493
13.

Targeted gene knock in and sequence modulation mediated by a psoralen-linked triplex-forming oligonucleotide.

Majumdar A, Muniandy PA, Liu J, Liu JL, Liu ST, Cuenoud B, Seidman MM.

J Biol Chem. 2008 Apr 25;283(17):11244-52. doi: 10.1074/jbc.M800607200. Epub 2008 Feb 25.

14.

Extensive sugar modification improves triple helix forming oligonucleotide activity in vitro but reduces activity in vivo.

Alam MR, Majumdar A, Thazhathveetil AK, Liu ST, Liu JL, Puri N, Cuenoud B, Sasaki S, Miller PS, Seidman MM.

Biochemistry. 2007 Sep 4;46(35):10222-33. Epub 2007 Aug 11.

PMID:
17691818
15.

Targeted cross-linking of the human beta-globin gene in living cells mediated by a triple helix forming oligonucleotide.

Shahid KA, Majumdar A, Alam R, Liu ST, Kuan JY, Sui X, Cuenoud B, Glazer PM, Miller PS, Seidman MM.

Biochemistry. 2006 Feb 14;45(6):1970-8.

PMID:
16460044
16.

In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.

Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, McEvoy L, Turner RJ, Trifilieff A.

J Pharmacol Exp Ther. 2006 May;317(2):762-70. Epub 2006 Jan 24.

PMID:
16434564
17.

The development of bioactive triple helix-forming oligonucleotides.

Seidman MM, Puri N, Majumdar A, Cuenoud B, Miller PS, Alam R.

Ann N Y Acad Sci. 2005 Nov;1058:119-27. Review.

PMID:
16394131
18.

Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate esters.

Sandham DA, Barker L, Beattie D, Beer D, Bidlake L, Bentley D, Butler KD, Craig S, Farr D, Ffoulkes-Jones C, Fozard JR, Haberthuer S, Howes C, Hynx D, Jeffers S, Keller TH, Kirkham PA, Maas JC, Mazzoni L, Nicholls A, Pilgrim GE, Schaebulin E, Spooner GM, Stringer R, Tranter P, Turner KL, Tweed MF, Walker C, Watson SJ, Cuenoud BM.

Bioorg Med Chem. 2004 Oct 1;12(19):5213-24.

PMID:
15351404
19.

Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the beta2-adrenoceptor activity.

Alikhani V, Beer D, Bentley D, Bruce I, Cuenoud BM, Fairhurst RA, Gedeck P, Haberthuer S, Hayden C, Janus D, Jordan L, Lewis C, Smithies K, Wissler E.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4705-10.

PMID:
15324892
20.

Importance of clustered 2'-O-(2-aminoethyl) residues for the gene targeting activity of triple helix-forming oligonucleotides.

Puri N, Majumdar A, Cuenoud B, Miller PS, Seidman MM.

Biochemistry. 2004 Feb 10;43(5):1343-51.

PMID:
14756571
21.

Gene targeting by triple helix-forming oligonucleotides.

Majumdar A, Puri N, McCollum N, Richards S, Cuenoud B, Miller P, Seidman MM.

Ann N Y Acad Sci. 2003 Dec;1002:141-53.

PMID:
14751832
22.

Cell cycle modulation of gene targeting by a triple helix-forming oligonucleotide.

Majumdar A, Puri N, Cuenoud B, Natt F, Martin P, Khorlin A, Dyatkina N, George AJ, Miller PS, Seidman MM.

J Biol Chem. 2003 Mar 28;278(13):11072-7. Epub 2003 Jan 21.

23.

Minimum number of 2'-O-(2-aminoethyl) residues required for gene knockout activity by triple helix forming oligonucleotides.

Puri N, Majumdar A, Cuenoud B, Natt F, Martin P, Boyd A, Miller PS, Seidman MM.

Biochemistry. 2002 Jun 18;41(24):7716-24.

PMID:
12056903
24.

Stable DNA triple helix formation using oligonucleotides containing 2'-aminoethoxy,5-propargylamino-U.

Sollogoub M, Darby RA, Cuenoud B, Brown T, Fox KR.

Biochemistry. 2002 Jun 11;41(23):7224-31.

PMID:
12044153
25.
26.

Targeted gene knockout by 2'-O-aminoethyl modified triplex forming oligonucleotides.

Puri N, Majumdar A, Cuenoud B, Natt F, Martin P, Boyd A, Miller PS, Seidman MM.

J Biol Chem. 2001 Aug 3;276(31):28991-8. Epub 2001 Jun 1.

27.

Inhibition of interleukin-4- and CD40-induced IgE germline gene promoter activity by 2'-aminoethoxy-modified triplex-forming oligonucleotides.

Stütz AM, Hoeck J, Natt F, Cuenoud B, Woisetschläger M.

J Biol Chem. 2001 Apr 13;276(15):11759-65. Epub 2001 Jan 19.

28.

Synthesis and hybridization properties of polyamide based nucleic acid analogues incorporating pyrrolidine-derived nucleoamino acids.

Altmann KH, Hüsken D, Cuenoud B, García-Echeverría C.

Bioorg Med Chem Lett. 2000 May 1;10(9):929-33.

PMID:
10853662
30.

Dual Recognition of Double-Stranded DNA by 2'-Aminoethoxy-Modified Oligonucleotides.

Cuenoud B, Casset F, Hüsken D, Natt F, Wolf RM, Altmann KH, Martin P, Moser HE.

Angew Chem Int Ed Engl. 1998 May 18;37(9):1288-1291. doi: 10.1002/(SICI)1521-3773(19980518)37:9<1288::AID-ANIE1288>3.0.CO;2-U.

PMID:
29711228
31.

A DNA metalloenzyme with DNA ligase activity.

Cuenoud B, Szostak JW.

Nature. 1995 Jun 15;375(6532):611-4.

PMID:
7791880
32.
33.

Altered specificity of DNA-binding proteins with transition metal dimerization domains.

Cuenoud B, Schepartz A.

Science. 1993 Jan 22;259(5094):510-3.

PMID:
8424173
34.

Conformation-dependent cleavage of staphylococcal nuclease with a disulfide-linked iron chelate.

Ermácora MR, Delfino JM, Cuenoud B, Schepartz A, Fox RO.

Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6383-7.

Supplemental Content

Loading ...
Support Center